Directly comparing randomized and real-world controls in adjuvant breast cancer.

Brigham Walker¹, Marley Boyd², Michelle Silver³, Junxin Shi⁴, Purva Bulsara⁴, Nino Balanchivadze⁵, Nicholas J Robert⁴

¹Department of Health Policy and Management, Tulane University Celia Scott Weatherhead School of Public Health, LA 70112, USA.

²TriNetX, MA 02140, USA.

³Genesis Research, NJ 07030, USA.

⁴Ontada, MA 02109, USA.

⁵Virginia Oncology Associates, US Oncology Network, VA 23502, USA.

PubMed PMC DOI PDF

Abstract

Aim: We sought to directly compare contemporaneous real-world (RW) and randomized controlled trial (RCT) control arms to assess the feasibility of utilizing RW controls in early breast cancer treatment. Materials & methods: Women with human epidermal growth factor receptor 2-negative high-risk breast cancer receiving adjuvant docetaxel, doxorubicin and cyclophosphamide for six cycles between 29 Ma…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.